Pathogenetic justification of immunocorrection in patients with erysipelas, depending on the form and features of the disease course
DOI:
https://doi.org/10.11603/2414-4533.2022.4.13601Keywords:
erysipelas, cellular link of the system, immunomodulatorsAbstract
The aim of the work: to study of the state of the cellular link of the immune system in patients with various forms and course of erysipelas with further justification of the appointment of immunomodulators.
Materials and Methods. We examined 130 patients with erysipelas of the face, upper and lower extremities. To assess the immune status, subpopulations of lymphocytes were determined using monoclonal antibodies to antigens CD3+ (T-lymphocytes), CD4+ (T-helpers), CD8+ (T-suppressors), CD16+ (killer cells), DM22+ (mature B-lymphocytes), and the immunoregulatory index (IRI) of DM4+/DM8+ was also calculated. Determination was carried out with reagents of the Kharkiv company "Granum". To detect disorders of the immune system, a universal method of assessing immune disorders, developed by рrofessor A.M. Zemskov, was used. (1996).
Results and Discussion. As a result of the research, it was established that all forms of primary and recurrent erysipelas (the bullous form is an exception) occurred against the background of secondary immunodeficiency. The degree of immune disorders varied depending on the severity of the course of the disease. Primary erysipelas with erythematous and bullous forms is characterized by the I degree of immune disorders, while primary erysipelas complicated by sepsis and phlegmonous-necrotic form in the primary and recurrent course is characterized by the II degree, and the recurrent course complicated by sepsis is characterized by the III degree of immune disorders.
Patients with pyelonephritis of all forms occurring against the background of secondary immunodeficiency in the first degree of immune disorders (which is obviously a transient state) do not need correction with immunomodulators, while patients with II and III degrees of immune disorders, being immunologically compromised, require mandatory prescription of immunomodulators (both biological and synthetic origin).
References
Bashkina, O.A., Samotrueva, M.A., Azhikova, A.K., & Pakhnova, L.R. (2019). Neiroimmunoendokrinnaya regulyatsiya fiziologicheskikh i patofiziologicheskikh protsessov v kozhe [Neuroimmunoendocrine regulation of physiological and pathophysiological processes in the skin]. Meditsinskaya immunologiya – Medical Immunology, 21(5), 807-820 [In Russian].
Brazhnik, Ye.A., & Ostroushko, A.P. (2016). Rozhistoe vospalenie v khirurgicheskoi praktike [Erysipelas in surgical practice]. Nauchnoe obozrenie. Meditsinskie nauki – Scientific review. Medical Sciences, (4), 14-17 [In Russian].
Gopatsa, G.V., & Yermakova, L.A. (2016). Rozha: sovremennoe sostoyanie problem [Erysipelas: the current state of the problem]. Nauchnii almanakh – Scientific Almanac., 1-2, 364-366 [In Russian].
Yemelyanov, A.S., Yemelyanova, A.N., Pushkarev, B.S., & Vitkovskii, Yu.A. (2018). Polimorfizm promotornogo regiona rs1800629 gena TNFα i yego vliyanie na soderzhanie faktora nekroza opukholei alfa v krovi zdorovikh lits i bolnikh rozhei [Polymorphism of the promoter region rs1800629 of the TNFα gene and its effect on the content of tumor necrosis factor alpha in the blood of healthy individuals and patients with erysipelas]. Meditsinskaya immunologiya – Medical Immunology, 20(3), 411-416 [In Russian].
Zemskov, A.M., Zemskov, V.M., Chereshnev, V.A., Reshetnikov, S.S., Galimzyanov, Kh. M., & Zemskova, V. A. (2011). Rukovodstvo po klinicheskoi immunologii dlya prakticheskikh vrachei [A Guide to Clinical Immunology for Practitioners]. Moscow: Triada-Kh. [In Russian].
Nikolov, V.V., Ospanbekova, N.K., Denefil, Ye.V., Pokrishko, Ye.V., Vlchev, V.I., Guleva, D.V., & Marina, S.S. (2015). Immunnie i neiroregulyatornie narusheniya pri rozhistoi infektsii [Immune and neuroregulatory disorders in erysipelas]. Klinichna imunolohiya, alerholohiya, infektolohiya – Clinical Immunology, Allergology, Infectology, 1, 43-48 [In Russian].
Ratnikova, L.I., Ship, S.A., Bespalova, M.K., & Garifanova, A.R. (2016). Komorbidnost rozhi i endokrinnikh zabolevanii [Comorbidity of erysipelas and endocrine diseases]. Nauchnii almanakh – Scientific Almanac., 5-3(19), 341-346 [In Russian].
Cherkasov, V.L. (1986). Rozha [Erysipelas]. Leningrad: Meditsina [In Russian].
Li, A., Wang, N., Ge, L., Xin, H., & Li, W. (2021). Risk factors of recurrent erysipelas in adult Chinese patients: a prospective cohort study. BMC Infectious Diseases, 21, 1-7.
Bruun, T., Oppegaard, O., Hufthammer, K. O., Langeland, N., & Skrede, S. (2016). Early response in cellulitis: a prospective study of dynamics and predictors. Clinical Infectious Diseases, 63(8), 1034-1041.
Falcone, M., Concia, E., Giusti, M., Mazzone, A., Santini, C., Stefani, S., & Violi, F. (2016). Acute bacterial skin and skin structure infections in internal medicine wards: old and new drugs. Internal and Emergency Medicine, 11, 637-648.
Inghammar, M., Rasmussen, M., & Linder, A. (2014). Recurrent erysipelas-risk factors and clinical presentation. BMC infectious diseases, 14(1), 1-6.
Jendoubi, F., Rohde, M., & Prinz, J.C. (2019). Intracellular streptococcal uptake and persistence: a potential cause of erysipelas recurrence. Frontiers in Medicine, 6, 6.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Hospital Surgery. Journal named by L.Ya. Kovalchuk
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish their work in Hospital Surgery. Journal by L. Ya. Kovalchuk agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
